Aimmune Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$540M
Industry:Biotech
Founded:2011
Lead Investor(s):KKR

City Ranking

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Aimmune Therapeutics's estimated annual revenue is currently $30.7M per year.
  • Aimmune Therapeutics received $170.0M in venture funding in January 2019.
  • Aimmune Therapeutics's estimated revenue per employee is $81,622
  • Aimmune Therapeutics's total funding is $540M.

Employee Data

  • Aimmune Therapeutics has 376 Employees.
  • Aimmune Therapeutics grew their employee count by 19% last year.
  • Aimmune Therapeutics currently has 13 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
DiaCarta
$7M4510%N/A-N/A
Geron Corporati...
N/A205N/AN/A-N/A
Rigel Pharmaceu...
$46.8M3024%N/A-N/A
Althea Technolo...
$22.3M144N/AN/A-N/A
INOVA Diagnosti...
$44.3M286N/AN/A-N/A
10X Genomics
$101.2M65346%N/A-N/A
ProTrials Resea...
$33.3M2153%N/A-N/A
Advanced Cell D...
$28.7M1858%N/A-N/A
The J. Craig Ve...
$39.4M254N/AN/A-N/A
CellMax Life
$6.5M4214%N/A-N/A
Missing a competitor? Contribute!?
Submit

Aimmune Therapeutics, a clinical-stage biopharmaceutical company, is developing desensitization treatments to help protect people with food allergies by potentially reducing the risk of allergic reactions, making accidental exposures to food allergens less dangerous. We are currently conducting Phase 3 studies of our lead product, AR101 for the treatment of peanut allergy. Aimmune is located in Brisbane, California - the heart of San Francisco's biotechnology hub - with additional offices in the Kings Cross area of London and in Raleigh, North Carolina.

keywords:Biotechnology,Food & Beverages,Healthcare,Pharmaceuticals

376

Number of Employees

$30.7M

Revenue (est)

13

Current Jobs

19%

Employee Growth %

$540M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Aimmune Therapeutics News

09/04/2019 - 7 things to know about Aimmune's peanut allergy therapy ...

13, will be a pivotal moment for Aimmune Therapeutics (AIMT 5), the biopharma company that developed the new treatment, called AR101.

08/08/2019 - Aimmune Therapeutics Announces Second Quarter 2019 ...

BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food ...

08/09/2019 - Aimmune Therapeutics, Inc. (AIMT) Q2 2019 Earnings Call ...

Operator. Good afternoon, ladies and gentlemen, and welcome to the Aimmune Therapeutics, Second Quarter 2019 Earnings Conference Call.

Aimmune Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-11-07$145.0MNestlé Health SciencNestlé Health ScienceArticle
2018-02-21$177.5MUndisclosedArticle
2018-11-29$98.0MUndisclosedNestlé Health ScienceArticle
2019-01-07$170.0MUndisclosedKKRArticle

Aimmune Therapeutics Executive Hires

DateNameTitleReference
2015-10-12Howard RaffConsultantArticle
2016-04-06Douglas SheehyGeneral Counsel/SecretaryArticle
2016-06-22Daniel AdelmanChief Medical OfficerArticle
2017-04-14Eric BjerkholtChief Financial OfficerArticle
2018-06-12Jayson DallasPresident and Chief Executive OfficerArticle
2019-01-21Andrew OxtobyChief Commercial OfficerArticle